Drug intelligence / Profile preview

ICG134

Development stage: Unknown
Lead developer: First Affiliated Hospital of Xiamen University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ICG134 is an experimental chimeric antigen receptor (CAR) T-cell therapy targeting CARVAC, developed by The First Affiliated Hospital of Xiamen University. It is being investigated as part of the SuperCARTRRB1.0 protocol for the treatment of relapsed or refractory B-cell malignancies, including B-cell lymphoma and acute B-lymphoblastic leukemia. In clinical studies, ICG134 is typically evaluated in combination with ICG132, a CAR-T therapy targeting CD19 and CD20, to provide a multi-antigen approach aimed at reducing the risk of relapse due to antigen loss. The therapy is currently in early-phase clinical development to assess safety and preliminary efficacy in patients with advanced B-cell cancers.

Beyond the preview

Go deeper on ICG134.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICG134.

Explore the full profile